Allergen reference doses for precautionary labeling (VITAL 2 Allergen reference doses for precautionary labeling (VITAL 2.0): Clinical implications Katrina J. Allen, MD, PhD, FAAAAI, Benjamin C. Remington, BS, Joseph L. Baumert, PhD, Rene W.R. Crevel, DIBT, Geert F. Houben, PhD, Simon Brooke-Taylor, PhD, Astrid G. Kruizinga, MSc, Steve L. Taylor, PhD Journal of Allergy and Clinical Immunology Volume 133, Issue 1, Pages 156-164 (January 2014) DOI: 10.1016/j.jaci.2013.06.042 Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions
Fig 1 Dose-distribution models for individual thresholds (expressed as milligrams of protein) based on allergic patients for diagnostic studies, threshold studies, and immunotherapy studies: A, peanut; B, milk. Journal of Allergy and Clinical Immunology 2014 133, 156-164DOI: (10.1016/j.jaci.2013.06.042) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions
Fig 2 Dose-distribution models for individual thresholds (expressed as milligrams of protein) based on geographic location: A, peanut; B, milk. Journal of Allergy and Clinical Immunology 2014 133, 156-164DOI: (10.1016/j.jaci.2013.06.042) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions
Fig 3 Probability distribution models for individual thresholds (expressed as milligrams of protein) based on age of the allergic patient at challenge: A, peanut; B, hazelnut. Journal of Allergy and Clinical Immunology 2014 133, 156-164DOI: (10.1016/j.jaci.2013.06.042) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions